This study was a phase one clinical trial in which six patients with radiologic evidence of knee osteoarthritis (OA) that required joint replacement surgery were recruited. The main objective of this phase was to evaluate treatment safety. A large controlled trial, however, is necessary to compare intra-articular MSC injection with standard of care.
In conclusion, it could be said that intra-articular injection of culture-expanded MSCs in OA knees would be a promising way to reduce the signs of this disorder and lead to patient satisfaction. Furthermore, this therapy possesses the potential of regenerating destructed articular cartilage in an osteoarthritic knee. According to our results, all evaluated parameters appeared to progressively improve up to six months post-injection. This value was slightly reduced until 12 months post-injection. For this reason, it can be concluded that a second injection would be needed six months after the first injection.